ELI LILLY & Co (LLY) Aktienanalyse
HealthcarePharmaceutical Preparations
| $65.18B |
| $45.04B |
| $34.12B |
| $28.54B |
| $28.32B |
| $24.54B |
| $6.11B |
| $5.64B |
| $6.16B |
| $5.76B |
| $5.38B |
| $5.12B |
| $5.81B |
| $22.60B |
| $24.29B |
| $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B | $1.28B | $1.13B | $1.62B | $1.47B | $1.39B | $1.25B | $1.39B | $4.80B | $5.07B |
| $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $6.11B | $5.64B | $6.16B | $5.76B | $5.38B | $5.12B | $5.81B | $22.60B | $24.29B |
| $11.09B | $8.59B | $7.40B | $6.44B | $6.43B | $6.12B | $6.21B | $5.98B | $6.59B | $6.45B | $6.53B | $6.62B | $7.13B | $7.51B | $7.88B |
| N/A | N/A | N/A | $7.19B | $7.03B | $6.09B | $5.60B | $5.05B | $5.28B | $5.24B | $4.80B | $4.73B | $5.53B | $5.28B | $5.02B |
Operativer Zinsaufwand | $571.00M | $218.60M | $485.90M | $331.60M | $339.80M | $359.60M | $400.60M | $242.50M | $225.00M | $185.20M | $161.20M | $148.80M | $160.10M | $177.80M | $186.00M |
|---|
| $11.05B | $8.42B | $7.08B | $13.82B | $14.34B | $11.57B | $3.28B | $3.09B | $3.25B | $3.24B | $3.24B | $2.99B | $3.43B | $5.28B | $5.02B |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Nicht-operativer Zinsaufwand | $895.00M | $780.60M | $485.90M | $331.60M | $339.80M | $359.60M | $400.60M | $242.50M | $225.00M | $185.20M | $161.20M | $148.80M | $160.10M | $177.80M | $186.00M |
|---|
Netto nicht-operativer Zinsertrag/-aufwand | -$895.00M | -$605.40M | -$312.30M | -$268.80M | -$314.40M | -$326.60M | -$320.20M | -$83.20M | -$57.70M | -$76.50M | -$74.20M | -$27.80M | -$40.40M | -$72.80M | -$106.10M |
|---|
Sonstige Erträge und Aufwendungen | -$571.00M | -$218.60M | $96.70M | -$320.90M | -$201.60M | $1.17B | $291.60M | $145.60M | $52.40M | $15.80M | $44.70M | $137.20M | $9.10M | $674.00M | -$179.00M |
|---|
Zinsertrag netto | -$895.00M | -$605.40M | -$312.30M | -$268.80M | -$314.40M | -$326.60M | -$320.20M | -$83.20M | -$57.70M | -$76.50M | -$74.20M | -$27.80M | -$40.40M | -$72.80M | -$106.10M |
|---|
Ergebnis vor Steuern (EBT) | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B | $7.23B | $5.27B | $3.68B | $2.20B | $3.37B | $2.79B | N/A | N/A | $4.90B | N/A |
|---|
Ertragsteuern | $5.09B | $2.09B | $1.31B | $561.60M | $573.80M | $1.04B | $167.40M | -$189.80M | $1.94B | $636.40M | $381.60M | $609.80M | $1.20B | $1.32B | $1.00B |
|---|
Ergebnis aus fortgeführten Geschäftsbereichen | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $5.10B | $3.87B | $256.40M | $2.74B | $2.41B | -$609.80M | -$1.20B | $3.58B | -$1.00B |
|---|
| $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | -$204.10M | $771.80M | $478.40M | $428.50M | $727.50M | $4.09B | $4.35B |
| $2.00B | $1.77B | $1.53B | $1.52B | $1.55B | $1.32B | $1.23B | $1.61B | $1.57B | $1.50B | $1.43B | $1.38B | $1.45B | $1.46B | $1.37B |
Abschreibungen | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B | $1.32B | $1.23B | $1.61B | $1.57B | $1.50B | $1.43B | $1.38B | $1.45B | $1.46B | $1.37B |
|---|